CN1162174C - Medicine for treating diabetes - Google Patents

Abstract

The present invention relates to a Chinese patent medicine for treating diabetes with Chinese herbal medicine as a raw material. The medicine of the present invention is formed by the combined prescription of Chinese herbal medicines which have the scientificity of the modern pharmacology and the experience of the traditional medicine, wherein the Chinese herbal medicines comprise wolfberry fruit, american ginseng, trichosanthes root, schisandra, kudzu and atractylis; besides, matrimony vine polysaccharide which is an effective ingredient is extracted by modern technology; thus, the dosage of the medicine is reduced, the interaction of the medicines is enhanced, and the resistibility of insulin is overcome. Thereby, the effective treatment rate is raised. The present invention has the advantages of low cost and no side effect. In addition, the medicine of the present invention has obvious effects on type 2 diabetes, the secondary delusion failure of sulphanylureas medicine and insulin resistance syndrome.

Description

A kind of medicine for the treatment of diabetes

Technical field

The present invention relates to a kind of medicine for the treatment of diabetes, specifically is the Chinese patent medicine that raw material is made with the Chinese herbal medicine.

Background technology

Diabetes (DM) are that insulin relatively or absolute the shortage causes sugar, fat, protein metabolism disorder and the metabolic disease that causes in the blood, and it occurs symptoms such as hyperglycemia, hyperlipidemia and hyperlipidemia in earlier stage, and extensively microangiopathies of the whole body appears in middle and advanced stage; Long, the difficult radical cure of onset diabetes rate height, the course of disease, its complication is many and heavy, and as diabetic nephropathy, diabetic hepatopathy, diabetic retinopathy, extremity gangrenous necrosis or the like, some disease can directly cause the mankind to disable or cause death; At present, diabetics has surpassed 200,000,000 people in the world, and China surpasses 20,000,000, and the trend that rises is year by year arranged, and therefore, diabetes have become and are only second to malignant tumor and cardiovascular diseases, jeopardize the third-largest disease of human life's health.

At present, treatment of diabetes is mainly taked orally-taken blood sugar reducing class medicine (glyburide, diamicron etc.) or is carried out injection of insulin, but secondary failure of the oral sulfonylureas drugs for diabetes of Chan Shenging (SF) and insuline resistance syndrome (IRS) have become the new treatment difficult point of treatment diabetes thereupon.

In recent years, thiazolidine diketone derivative class medicine, comprise rosiglitazone (Rosiglitazone), pioglitazone (Pioglitazone), troglitazone (Troglitazone) etc., become the new drug of treatment diabetes, this quasi drugs not only has blood sugar lowering, hypotensive effect to type ii diabetes (claiming non-insulin-dependent diabetes mellitus again), and can alleviate insulin resistant, the beta Cell of islet excreting insulin had enhancement effect, thereby the effectively generation of angiocardiopathy preventing reduces case fatality rate, improves the control of clinical diabetes; But such poisonous side effect of medicine is big, and is particularly serious to the infringement of liver, even can cause hepatic necrosis, and, this type of drug price costliness.

Summary of the invention

The objective of the invention is to overcome the defective of above-mentioned prior art, provide a kind of to type ii diabetes, secondary failure that oral sulfonylureas drugs for diabetes produces and insuline resistance syndrome all have significant curative effect, and cheap, as to have no side effect natural insulin sensitizer, treatment Glucovance promptly of the present invention.

Technical scheme of the present invention is:

A kind of medicine for the treatment of diabetes, this medicine are to be made by the following weight proportion raw material:

Lycium barbarum polysaccharide 4.5-5.5 part

Radix Panacis Quinquefolii 4.5-5.5 part

Radix Trichosanthis 1-100 part

Fructus Schisandrae Chinensis 1-100 part

Radix Puerariae 1-100 part

Rhizoma Atractylodis 1-100 part;

Preferred weight ratio range of the present invention can be:

Lycium barbarum polysaccharide 4.5-5.5 part

Radix Panacis Quinquefolii 4.5-5.5 part

Radix Trichosanthis 40-60 part

Fructus Schisandrae Chinensis 40-60 part

Radix Puerariae 40-60 part

Rhizoma Atractylodis 40-60 part;

Optimum weight proportioning of the present invention is:

5 parts of lycium barbarum polysaccharide

50 parts of Radix Panacis Quinquefoliis

50 parts of Radix Trichosanthis

50 parts of Fructus Schisandrae Chinensis

50 parts of Radix Puerariaes

45 parts of Rhizoma Atractylodis.

American diabetes association (ADA) in 1997 and The World Health Organization (WHO) in 1999 propose new diabetes (DM) classification and diagnostic criteria respectively, the core of emphasizing human diabetes, IGT (blood glucose or glucose in urine are higher, but do not reach the diabetes category) and relevant disease is inherited genetic factors and relevant environment results of interaction; Technical scheme of the present invention just is being based on more above-mentioned, to diabetes and correlated metabolism diseases: the control that hypertension, coronary heart disease, apoplexy, nephropathy change, microalbuminuria, hyperlipidemia, blood is sticking to be equal to the interaction result that respective environment changes has unusually been done to consider as a whole, incidence rate or case fatality rate with the reduction cardiovascular event are general objective, from the glucose-lowering treatment diabetes is main, redirecting to and preventing and treating cardiovascular risk factors comprehensively is purpose, finally reaches: 1. the prevalence that reduces the II paradiabetes; 2. reduce diabetes trunk and the incidence rate of microvascular complication and the case fatality rate of diabetes relevant disease; 3. improve the life quality of diabetics; 4. reduce the treatment of diabetes expense to greatest extent.

Therefore, the raw material that the present invention is selected from the pharmacological property to the price factor, all is to be direction with above-mentioned target, reduces medical expense to greatest extent, improves clinical cure rate, and can carry out early stage pharmaceutical intervention treatment, to play preventive effect.

The medicine that the present invention is selected, each tool effect, as:

1, Fructus Lycii

Fructus Lycii and effective ingredient thereof---lycium barbarum polysaccharide has 1) obviously blood sugar lowering effect, its blood sugar lowering effective percentage can reach 100%; 2) strengthen immune function of human body, promote and improve peripheral blood T lymphocyte percentage; 3) can promote, improve and recover the beta Cell of islet excreting insulin and increase insulin sensitivity; 4) traditional medicine is thought, Fructus Lycii have nourishing kidney tonifying the lung, tonification disappear in, control asthenia, quench one's thirst and effect such as end.

2, Radix Panacis Quinquefolii

Contain the people in the Radix Panacis Quinquefolii and join Suds glycoside, panaxynol, Radix Ginseng training hemiterpene alkene, panax acid, plant sterol, polysaccharide, choline and each seed amino acid, trace element etc., it has 1) suppress blood sugar increasing significantly, reduce blood middle reaches ion fatty acids (FFA), alleviate " lipid toxicity " detrimental effect, can prevent trunk and microvascular arteriosclerosis islet cells; 2) generation, the development of the gene mutation of II paradiabetes be can suppress, and maintenance and protective effect played; 3) can promote sugared metabolism, especially can promote glycogenolysis or suppress the release that lactic acid synthesizes hepatic glycogen, makes lactic acid minimizing and promotion insulin, therefore, the people participates in insulin and has synergism---and promptly strengthen the sensitivity of insulin, can reduce or reduce insulin resistant; 4) traditional medicine is thought, Radix Panacis Quinquefolii has strongly invigorating primordial QI, promote the production of body fluid admittedly take off, and sedative action, it is deficient to cure mainly impairment caused by overstrain, the disease of qi-blood-body fluid deficiency such as quench one's thirst.

3, Fructus Schisandrae Chinensis

Contained schizandrin is to free-radical generating propylhomoserin system and CCl in the Fructus Schisandrae Chinensis ₄The damage of the lipid oxidation of the liver that causes, pancreatic cell film has protective effect, and catabolites such as lipid, steroid are entered the exogenous material of human body, plays inducing action as the end last conversion process of Insulin receptor INSR; 3) can promote carbohydrate metabolism; 4) traditional medicine is thought, Fructus Schisandrae Chinensis has promoting the production of body fluid to quench thirst, effects such as QI invigorating nourishing kidney.

4, Radix Trichosanthis Rhizoma Atractylodis Radix Puerariae

Radix Trichosanthis has the promoting the production of body fluid to quench thirst effect; Rhizoma Atractylodis can play the blood sugar lowering effect; Radix Puerariae can reach the effect of steady decrease blood glucose.

The present invention is with the above-mentioned science that had both had modern pharmacology, the empirical Chinese herbal medicine associating prescription that has traditional medicine again, and selected active ingredient---the lycium barbarum polysaccharide of extracting through modern crafts for use, to reduce dosage, strengthen the interaction between medicine, overcome resistance of insulin and reducing, thereby improved effective treatment rate.

Medicine of the present invention is through clinical use, and its advantage is embodied in:

1. contain multiple human body essential amino acid in the medicine of the present invention, both can promote insulin to discharge, can strengthen patient's body constitution again;

2. medicine of the present invention has tangible blood sugar lowering, effect for reducing fat, and is especially remarkable to II paradiabetes and insuline resistance syndrome effect;

3. medicine of the present invention can stop and delay the secondary failure of sulfonylurea drugs, and can make the sulfonylurea drugs of inefficacy bring into play drug effect again;

4. the selected medicine of the present invention is natural Chinese medicinal herb, and is with low cost, and has no side effect;

5. the present invention can be made into capsule, and is for oral administration, easy, is beneficial to absorption, and easy to carry;

6. medicine of the present invention is taken for a long time, can play the early prevention effect;

7. medicine of the present invention can be used as the paramedicines of treatment I paradiabetes.

In order to show this medicine to treatment treatment of diabetes effect, the present invention selects through regular treatment, data record complete, follows up a case by regular visits to outpatient service more than 3 months, is in hospital and community family sick bed II paradiabetes patient 1154 examples, and it is divided into:

Matched group: 642 conventional oral sulphanylureas of example or contain the patient of sulphanylureas composition antidiabetic drug;

Treatment A group: 85 routine oral sulphanylureas or contain sulphanylureas composition antidiabetic drug and produce the patient who adds this medicine behind the secondary failure;

Treatment B group: 427 examples, the patient of an oral first medicine.

Diagnostic criteria adopts World Health Organization (WHO) in 1999 about diabetes diagnosis classification and standard, adopts the blood glucose value of Jian Ce Static arteries and veins blood plasma without exception.

1. evaluation criterion: after all kinds of antidiabetic drug 1-3 months, it is standard that laboratory report blood glucose value (FPG, PPG) and clinical symptoms are controlled the improvement degree, carries out the clinical therapeutic efficacy evaluation with single clothes or connection clothes.

Produce effects: FPG＜7.2mmol/L, PPG＜8.3mmol/L, clinical symptoms disappears substantially;

Effectively: FPG＜8.3mmol/L, PPG＜10.0mmol/L, clinical symptoms is clearly better;

Invalid: FPG＞10.0mmol/L, PPG＞11.1mmol/L, clinical symptoms does not have obvious improvement.

2. above-mentioned 1154 routine curative effect statistics

Group	The example number	Produce effects	％	Effectively	％	Invalid	％	Total effective rate
									Matched group	642	261	40.65	165	25.25	217	33.80	66.20
Treatment A group	85	42	49.41	34	40.00	9	10.59	89.41
									Treatment B group	427	276	64.64	151	29.74	24	5.62	94.38
Add up to	1154	579	50.17	349	33.11	240	20.80	81.28

Above-mentioned statistical result is learned by statistics to handle with matched group and is compared, and there is significant difference its P＜0.01, illustrates to adopt this drug treatment of diabetic, and especially the therapeutic effect of II paradiabetes is remarkable, and its total effective rate can reach 81.28%.

Also can draw by above-mentioned graphic analyses: adopt medicine of the present invention can solve because of taking the secondary failure of sulfonylurea drugs, sulfonylurea drugs is played a role again to the patient, and effective percentage rises to 89.41%, and takes this medicine merely, its cure rate is better, and effective percentage reaches 94.38%.

In sum, medicine of the present invention all has remarkable result to the secondary failure and the insuline resistance syndrome of II paradiabetes, oral sulfonylurea drugs.

The specific embodiment

Embodiment:

Take by weighing raw material by following proportioning:

Lycium barbarum polysaccharide 5g Radix Panacis Quinquefolii 50g

Radix Trichosanthis 50g Fructus Schisandrae Chinensis 50g

Radix Puerariae 50g Rhizoma Atractylodis 45g is then according to the conventional preparation method of Chinese medicine: pulverize, grind, sieve, mixing, ultra-vioket radiation etc., make capsule with every 0.25 gram weight, get final product.

Case history 1: diabetic history 17 years, check result: blood pressure 68/40mmHg, heart rate 54 times/minute, the electrocardiogram report: cardiovascular function is low, deficiency myocardial blood supply, the low blood of fighting, low heart pump power, Hypovolemia, high blood viscosity, FPG27.20mmol/L, clinical diagnosis: II paradiabetes, ketoacidosis, heart failure III level, serious dehydration, electrolyte disturbance and insuline resistance syndrome; Correct acidosis, dehydration and treatments such as electrolyte disturbance, makeup energy and vitamin C and the described medicine of oral embodiment through intravenous drip insulin, the saturating liquid of light quantum oxygen, after 10 days, check clinical, blood pressure 104/60mmHg, FPG5.6mmol/L, PPG6.17mmol/L, once more after the week, the insulin of stopping using, the bimester after, check fasting glucose 6.4mmol/L, 2 hours after the meal blood glucose 7.6mmol/L.

Case history 2: diabetic history 3 years, check result: FPG14.70mmol/L, PPG19.27mmol/L, the right lower extremity lateral femoral cutaneous nerve domination district and the skin pain sensation obviously weaken clinical diagnosis: pathological changes around the secondary failure of II paradiabetes, sulfonylurea drugs, insuline resistance syndrome and the diabetic nerve; Lead flat, massage, growth factor of human nerve acupoint injection therapy and the described medicine of oral embodiment through the computer acupuncture, clinical symptoms all disappears after three months, and quadriceps femoris and shank muscle group recover normally substantially, and PPG is controlled at 6.8-7.2mmol/L.

Case history 3: diabetic history 6 years, hypertension 5 years, check result: blood pressure 165/97mmHg, ECG ST section changes, 2.3 li pools of whole blood viscosity, 1.9 li pools of reduction whole blood viscosity, FPG11.8mmol/L, PPG17.1mmol/L, clinical diagnosis: II paradiabetes, insuline resistance syndrome (hypertension, coronary heart disease and low sticking mass formed by blood stasis); The described medicine of oral administration embodiment was checked FPG5.7mmol/L after 45 days, PPG7.1mmol/L, and the electrocardiogram report, roughly normal, PPG all is controlled at below the 7.8mmol/L after 6 months.

Case history 4: nearly two weeks comes tired unable, dizzy, the easy perspiration of conscious whole body, thirsty, appetite increase, check result: FPG31.00mmol/L, and blood pressure 167/99mmHg, electrocardiogram are normal substantially, clinical diagnosis: II paradiabetes, hypertension; The saturating liquid treatment of described medicine of oral administration embodiment and light quantum oxygen was checked FPG5.4mmol/L, PPG16.7mmol/L, blood pressure 132/85mmHg after 10 days.

Case history 5: diabetic nephropathy history 11 years, chronic urinary system infection 1 year, check result: blood pressure 141/90mmHg, electrocardiogram report: deficiency myocardial blood supply, FPG21.50mmol/L, PPG27.1mmol/L, urine protein (+++), cast (++), leukocyte (+++), erythrocyte (+), glucose in urine (+++), urine ketone (-), clinical diagnosis: II paradiabetes, insuline resistance syndrome (hypertension, coronary heart disease, nephropathy become and urinary tract infection); The saturating liquid treatment of the described medicine of oral administration embodiment, broad spectrum antibiotic and light quantum oxygen was checked clinical urinary system infection symptom basic controlling after 20 days, blood pressure 132/88mmHg, FPG6.9mmol/L, PPG7.6mmol/L, urine protein (+), glucose in urine (+), urine ketone (-).

Claims (3)

1. medicine for the treatment of diabetes is characterized in that this medicine is to be made by the following weight proportion raw material:

Lycium barbarum polysaccharide 4.5-5.5 part

Radix Panacis Quinquefolii 4.5-5.5 part

Radix Trichosanthis 1-100 part

Fructus Schisandrae Chinensis 1-100 part

Radix Puerariae 1-100 part

Rhizoma Atractylodis 1-100 part.

2. by the described a kind of medicine for the treatment of diabetes of claim 1, it is characterized in that the weight proportion of above-mentioned raw materials is:

Lycium barbarum polysaccharide 4.5-5.5 part

Radix Panacis Quinquefolii 4.5-5.5 part

Radix Trichosanthis 40-60 part

Fructus Schisandrae Chinensis 40-60 part

Radix Puerariae 40-60 part

Rhizoma Atractylodis 40-60 part.

3. by claim 1 or 2 described a kind of medicines for the treatment of diabetes, it is characterized in that the weight proportion of above-mentioned raw materials is:

5 parts of lycium barbarum polysaccharide

50 parts of Radix Panacis Quinquefoliis

50 parts of Radix Trichosanthis

50 parts of Fructus Schisandrae Chinensis

50 parts of Radix Puerariaes

45 parts of Rhizoma Atractylodis.